Literature DB >> 31697814

Brentuximab vedotin in the treatment of CD30+ PTCL.

Stefan K Barta1, Jerald Z Gong2, Pierluigi Porcu3.   

Abstract

The development of brentuximab vedotin has opened a new era in the management of peripheral T-cell lymphomas (PTCLs). The improved outcomes with brentuximab vedotin (BV) in combination with cyclophosphamide, doxorubicin, and prednisone (BV-CHP) vs cyclophosphamide, doxorubicin, vincristine, and prednisone in the ECHELON-2 trial are practice changing for common nodal CD30+ PTCLs. Questions regarding the optimal cutoff of CD30 expression for BV-CHP therapy and the efficacy and safety of BV-CHP in less common subtypes of CD30+ PTCL subtypes await clarification.
© 2019 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31697814     DOI： 10.1182/blood.2019001821

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas.

Authors:  Zachary Braunstein; Miguel Ruiz; Walter Hanel; Polina Shindiapina; John C Reneau; Jonathan E Brammer
Journal:  J Pers Med       Date:  2022-06-13

2.  A Rare Case of Aggressive Peripheral T-cell Lymphoma-Not Otherwise Specified.

Authors:  Ateeb Ur Rahman; Amna Chaudary; Sonia Varandani
Journal:  Cureus       Date:  2022-05-09

Review 3.  Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy.

Authors:  Ha Gyeong Shin; Ha Rim Yang; Aerin Yoon; Sukmook Lee
Journal:  Int J Mol Sci       Date:  2022-05-19       Impact factor: 6.208

4.  Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas.

Authors:  Gu Zhenyang; Li Nainong; Wu Xiaoxiong; Wang Maihong; Fu Xiaorui; Wang Zhao; Ren Hanyun; Li Yuhang; Li Xiaofan; Wu Yamei; Liu Yao; Zhang Mingzhi; Wang Yini; Liu Daihong; Dong Yujun; Hu Liangding; Huang Wenrong
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

Review 5.  A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies.

Authors:  Haley Newman; David T Teachey
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

6.  Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD).

Authors:  Jennifer Hong; William T Johnson; Saritha Kartan; Anitha S Gonsalves; Jonathan M Fenkel; Jerald Z Gong; Pierluigi Porcu
Journal:  Curr Oncol       Date:  2021-12-02       Impact factor: 3.677

Review 7.  The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively.

Authors:  Wen-Qian Li; Han-Fei Guo; Ling-Yu Li; Yong-Fei Zhang; Jiu-Wei Cui
Journal:  Cancer Med       Date:  2021-06-24       Impact factor: 4.452
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.